Creo Medical, a UK-based medical device company, has announced a significant milestone for its MicroBlate Flex technology, which has now been used in over 100 clinical cases across the United Kingdom. This innovative device employs microwave ablation to treat soft tissue lesions, including various types of cancer, offering a minimally invasive option for patients.
The MicroBlate Flex system delivers precise microwave energy directly into tumours, heating and destroying cancerous cells while aiming to minimise damage to surrounding healthy tissue. This approach can lead to several benefits for patients, such as reduced pain, shorter hospital stays, and quicker recovery times compared to traditional open surgery for certain conditions. The technology is particularly relevant for hard-to-reach tumours or for patients who may not be suitable candidates for more invasive surgical interventions.
The successful completion of over 100 cases highlights the growing adoption of this advanced technology within NHS trusts and private hospitals. Clinicians are increasingly exploring less invasive methods to improve patient outcomes and alleviate pressure on healthcare resources. The data gathered from these initial cases will be crucial in further evaluating the efficacy and broader applicability of MicroBlate Flex across a wider range of cancer types and patient demographics.
According to NHS England data, cancer remains a leading cause of mortality, with early diagnosis and effective treatment being paramount. Technologies like MicroBlate Flex align with the NHS's long-term plan to incorporate innovative solutions that enhance treatment pathways and patient experience. While not a universal solution for all cancers, its success in these initial cases suggests it could become a valuable tool in the multidisciplinary approach to cancer care.
The continued rollout and clinical evaluation of MicroBlate Flex will be closely watched by the medical community. As more hospitals adopt the technology and build expertise, it is anticipated that the number of patients benefiting from this minimally invasive treatment will continue to grow, potentially transforming care for specific cancer indications.